# Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

> **NCT00671658** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 220 (actual)

## Conditions studied

- Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate (MTX)
- **DRUG:** Cytarabine
- **DRUG:** G-CSF
- **DRUG:** Mesna
- **DRUG:** Pegylated asparaginase
- **DRUG:** Pegfilgrastim
- **DRUG:** Solumedrol

## Key facts

- **NCT ID:** NCT00671658
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2020-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671658, "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00671658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*